Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $99,950.76 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 5,876 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $17.01, for a total value of $99,950.76. Following the sale, the insider now owns 71,525 shares of the company’s stock, valued at approximately $1,216,640.25. The trade was a 7.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Centessa Pharmaceuticals Trading Up 6.3 %

Shares of NASDAQ CNTA opened at $17.55 on Friday. Centessa Pharmaceuticals plc has a twelve month low of $6.65 and a twelve month high of $18.97. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -11.47 and a beta of 1.52. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company’s fifty day moving average is $16.62 and its 200-day moving average is $13.51.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. Equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective for the company. Guggenheim boosted their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Jefferies Financial Group upped their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Finally, BMO Capital Markets raised their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC increased its position in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after acquiring an additional 1,509 shares in the last quarter. Quarry LP raised its holdings in shares of Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after acquiring an additional 3,108 shares during the period. Sandia Investment Management LP bought a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at $90,000. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals in the 2nd quarter worth $99,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.